JNJ catalyst calendar

JOHNSON & JOHNSON

Upcoming catalysts
50
Cash runway
Cash generating
Cash & investments
$20758M
Phase 3 programs
89

JOHNSON & JOHNSON is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies on October 30, 2026. There are 50 upcoming events on record.

JOHNSON & JOHNSON generates cash from operations, so a burn-based runway figure does not apply.

Across 415 concluded trials, 87% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 30, 2026 A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies Trial Milestone Phase 1
December 4, 2026 A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms Trial Milestone Phase 1
December 8, 2026 A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer Trial Milestone Phase 1
December 15, 2026 A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors Trial Milestone Phase 1
December 30, 2026 Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms Trial Milestone Phase 3
December 31, 2026 A Long-term Extension Study of PCI-32765 (Ibrutinib) Trial Milestone Phase 3
December 31, 2026 ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer Trial Milestone Phase 1
January 11, 2027 est. Next quarterly earnings (projected) Earnings —
March 31, 2027 A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Trial Milestone Phase 1
April 7, 2027 A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma Trial Milestone Phase 1
April 28, 2027 A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer Trial Milestone Phase 1/Phase 2
May 14, 2027 Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trial Milestone Phase 2/Phase 3
May 31, 2027 Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib Trial Milestone Phase 2
June 28, 2027 A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis Trial Milestone Phase 2
June 30, 2027 A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis Trial Milestone Phase 2/Phase 3
July 30, 2027 A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment Trial Milestone Phase 3
August 5, 2027 A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Trial Milestone Phase 3
August 5, 2027 A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms Trial Milestone Phase 1
September 29, 2027 A Long-term Extension Study of Ustekinumab in Pediatric Participants Trial Milestone Phase 3
December 15, 2027 A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) Trial Milestone Phase 3
December 15, 2027 A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia Trial Milestone Phase 2
January 1, 2028 Nipocalimab in Moderate to Severe Sjogren's Disease Trial Milestone Phase 3
January 19, 2028 A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring Trial Milestone Phase 1
March 30, 2028 Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer Trial Milestone Phase 1/Phase 2
June 12, 2028 A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease Trial Milestone Phase 3
June 28, 2028 A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer Trial Milestone Phase 3
August 11, 2028 A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis Trial Milestone Phase 3
August 17, 2028 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer Trial Milestone Phase 1/Phase 2
August 18, 2028 A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial Milestone Phase 3
August 24, 2028 A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder Trial Milestone Phase 3
August 31, 2028 A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies Trial Milestone Phase 1
September 19, 2028 A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease Trial Milestone Phase 2/Phase 3
November 15, 2028 A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Trial Milestone Phase 3
December 6, 2028 A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus Trial Milestone Phase 3
December 12, 2028 A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Trial Milestone Phase 3
December 27, 2028 A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression Trial Milestone Phase 3
January 2, 2029 A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma Trial Milestone Phase 1
January 31, 2029 A Study of Daratumumab Trial Milestone Phase 3
March 16, 2029 A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer Trial Milestone Phase 1
April 29, 2029 A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Trial Milestone Phase 3
May 18, 2029 A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies Trial Milestone Phase 1
May 23, 2029 A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Trial Milestone Phase 2
August 24, 2029 A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) Trial Milestone Phase 2/Phase 3
September 11, 2029 A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma Trial Milestone Phase 2
September 4, 2030 A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned Trial Milestone Phase 3
November 27, 2030 A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) Trial Milestone Phase 3
April 9, 2031 A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder Trial Milestone Phase 3
April 30, 2031 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma Trial Milestone Phase 3
December 12, 2031 A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants Trial Milestone Phase 3
July 30, 2041 A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma Trial Milestone Phase 1/Phase 2

Track JNJ alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open JNJ in the tracker

Recent history

DateEventTypePhase
October 13, 2026 Quarterly results filed (8-K) Earnings —
October 12, 2026 A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC Trial Milestone Phase 3
September 2, 2026 A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms Trial Milestone Phase 1
August 4, 2026 8-K filed: Leadership change Corporate —
July 29, 2026 8-K filed: Reg FD disclosure Filing —
July 28, 2026 8-K filed: Reg FD disclosure Filing —
July 15, 2026 Quarterly results filed (8-K) Earnings —
June 25, 2026 A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder Trial Milestone Phase 2
May 25, 2026 A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis Trial Milestone Phase 3
May 14, 2026 A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer Trial Milestone Phase 1/Phase 2
April 14, 2026 Quarterly results filed (8-K) Earnings —
April 1, 2026 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide Trial Milestone Phase 3
February 23, 2026 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) Trial Milestone Phase 2
January 30, 2026 A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer Trial Milestone Phase 1
January 21, 2026 Quarterly results filed (8-K) Earnings —
October 17, 2025 A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease Trial Milestone Phase 2
October 14, 2025 Quarterly results filed (8-K) Earnings —
October 3, 2025 A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma Trial Milestone Phase 1
September 25, 2025 Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma Trial Milestone Phase 1
September 16, 2025 A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors Trial Milestone Phase 1
September 9, 2025 8-K filed: Leadership change Corporate —
August 27, 2025 A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years Trial Milestone Phase 3
August 1, 2025 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma Trial Milestone Phase 3
July 16, 2025 Quarterly results filed (8-K) Earnings —
July 14, 2025 Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis Trial Milestone Phase 2
July 3, 2025 A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy Trial Milestone Phase 2
June 24, 2025 A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms Trial Milestone Phase 1
June 10, 2025 8-K filed: Leadership change Corporate —
May 28, 2025 A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Trial Milestone Phase 1
May 23, 2025 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.